As the TLR4 mediates inflammatory and pro‐fibrogenic signalling in HSC, the development of safe and efficient shRNA delivery vehicles targeted against the TLR4 to mitigate their signalling might serve as an efficient therapeutic agent for liver fibrosis. The gene discussed is TLR4; the disease is Hepatic fibrosis.